Sunday, December 07, 2014 1:48:14 PM
How are the insider trading numbers anything but negative? They do nothing but sell their shares. If they were aware of impending big contracts I suspect we would see a different trend. Why do you want retail investors to buy from insiders who don't seem to have much faith in their own company?
The institutional holdings numbers are better than I thought but still bad. Most shareholders are retail investors who think the idea is cool and who think they found a goldmine but don't realize that they seem to be donating to a research institution rather than investing in a company who plans to return value to shareholders anytime soon.
In the meantime please let me know if there is reason to believe that any pharmaceutical company is interested in these liver tissues because I have seen no evidence whatsoever.
This company should not be traded on the Nasdaq it doesn't seem to be anything but a research organization all I see is pr's about presentations and collaboration with academia.
The institutional holdings numbers are better than I thought but still bad. Most shareholders are retail investors who think the idea is cool and who think they found a goldmine but don't realize that they seem to be donating to a research institution rather than investing in a company who plans to return value to shareholders anytime soon.
In the meantime please let me know if there is reason to believe that any pharmaceutical company is interested in these liver tissues because I have seen no evidence whatsoever.
This company should not be traded on the Nasdaq it doesn't seem to be anything but a research organization all I see is pr's about presentations and collaboration with academia.
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
